Clinical Trial Update: Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic study assessed the PK of a single oral dose of ranolazine in patients with end-stage renal disease undergoing hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• End-stage Renal Disease

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: University of Michigan | Conditions: End-stage Renal Disease, Cardiovascular Disease | Phase 4 | Status: COMPLETED | Results posted: 2014-06-25